Medication Summary

The goals of therapy are to eradicate the infection, to reduce morbidity, and to prevent complications. A high index of suspicion is important, as doxycycline, the antibiotic of choice, is not usually a part of the empiric therapy for septicemia. Tigecycline may be a good choice for treating invasive V vulnificus infections.^[38]

If necrotizing fasciitis is suspected, early fasciotomy and culture-directed antimicrobial therapy should be performed. These patients may develop hypotensive shock, leukopenia, severe hypoalbuminemia, and underlying chronic illness, especially a combination of hepatic dysfunction and diabetes mellitus.

Class Summary

Antibiotics are necessary to eradicate V vulnificus infection. Effective antibiotics may include tetracycline, third-generation cephalosporins, and imipenem.

Doxycycline (Doryx, Vibramycin, Bio-Tab)

View full drug information

Doxycycline is a synthetic antibiotic derived from tetracycline. It inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. Doxycycline is effective against a large number of pathogens.

Questions

Lim PL. Wound infections in tsunami survivors: a commentary. Ann Acad Med Singapore. 2005 Oct. 34(9):582-5. [QxMD MEDLINE Link].
Park SY, Yu SN, Lee EJ, Kim T, Jeon MH, Choo EJ, et al. Monomicrobial gram-negative necrotizing fasciitis: An uncommon but fatal syndrome. Diagn Microbiol Infect Dis. 2019 Jan 4. [QxMD MEDLINE Link].
Phillips KE, Satchell KJ. Vibrio vulnificus: From Oyster Colonist to Human Pathogen. PLoS Pathog. 2017 Jan. 13 (1):e1006053. [QxMD MEDLINE Link].
Tiba-Casas MR, Lemes-Marques EG, Almeida EA, Soares FB, Camargo CH. Draft Genome Sequence of a Pathogenic Vibrio vulnificus Strain Isolated in Brazil. Genome Announc. 2018 Feb 15. 6 (7):[QxMD MEDLINE Link].
Rosche TM, Yano Y, Oliver JD. A rapid and simple PCR analysis indicates there are two subgroups of Vibrio vulnificus which correlate with clinical or environmental isolation. Microbiol Immunol. 2005. 49(4):381-9. [QxMD MEDLINE Link].
Broza YY, Raz N, Lerner L, Danin-Poleg Y, Kashi Y. Genetic diversity of the human pathogen Vibrio vulnificus: a new phylogroup. Int J Food Microbiol. 2012 Feb 15. 153(3):436-43. [QxMD MEDLINE Link].
Jones JL, Kinsey TP, Johnson LW, Porso R, Friedman B, Curtis M, et al. Effects of Intertidal Harvest Practices on Vibrio parahaemolyticus and Vibrio vulnificus Levels in Oysters. Appl Environ Microbiol. 2016 May 20. [QxMD MEDLINE Link].
Tra VT, Meng L, Pichpol D, Pham NH, Baumann M, Alter T, et al. Prevalence and antimicrobial resistance of Vibrio spp. in retail shrimps in Vietnam. Berl Munch Tierarztl Wochenschr. 2016 Jan-Feb. 129 (1-2):48-51. [QxMD MEDLINE Link].
Froelich BA, Williams TC, Noble RT, Oliver JD. Apparent Loss of Vibrio vulnificus from North Carolina Oysters Coincides with a Drought-Induced Increase in Salinity. Appl Environ Microbiol. 2012 Jun. 78(11):3885-9. [QxMD MEDLINE Link].
Barbieri R, Aboudharam G, Raoult D, Drancourt M. Vibrio vulnificus casualties during the American Civil War. Lancet Infect Dis. 2020 Feb. 20 (2):170-171. [QxMD MEDLINE Link].
Inoue Y, Ono T, Matsui T, Miyasaka J, Kinoshita Y, Ihn H. Epidemiological survey of Vibrio vulnificus infection in Japan between 1999 and 2003. J Dermatol. 2008 Mar. 35(3):129-39. [QxMD MEDLINE Link].
Sangeetha MS, Shekar M, Venugopal MN. Occurrence of clinical genotype Vibrio vulnificus in clam samples in Mangalore, Southwest coast of India. J Food Sci Technol. 2017 Mar. 54 (3):786-791. [QxMD MEDLINE Link].
Li G, Wang MY. The role of Vibrio vulnificus virulence factors and regulators in its infection-induced sepsis. Folia Microbiol (Praha). 2020 Apr. 65 (2):265-274. [QxMD MEDLINE Link].
Baker-Austin C, Oliver JD. Vibrio vulnificus: new insights into a deadly opportunistic pathogen. Environ Microbiol. 2018 Feb. 20 (2):423-430. [QxMD MEDLINE Link].
Hendren N, Sukumar S, Glazer CS. Vibrio vulnificus septic shock due to a contaminated tattoo. BMJ Case Rep. 2017 May 27. 2017:[QxMD MEDLINE Link].
Huang KC, Tsai YH, Huang KC, Lee MS. Model for End-Stage Liver Disease (MELD) Score as a Predictor and Monitor of Mortality in Patients with Vibrio vulnificus Necrotizing Skin and Soft Tissue Infections. PLoS Negl Trop Dis. 2015 Apr. 9 (4):e0003720. [QxMD MEDLINE Link].
Tsai YH, Huang TJ, Hsu RW, et al. Necrotizing soft-tissue infections and primary sepsis caused by Vibrio vulnificus and Vibrio cholerae non-O1. J Trauma. 2009 Mar. 66(3):899-905. [QxMD MEDLINE Link].
Kuo Chou TN, Chao WN, Yang C, Wong RH, Ueng KC, Chen SC. Predictors of Mortality in Skin and Soft-tissue Infections Caused by Vibrio vulnificus. World J Surg. 2010 Feb 12. [QxMD MEDLINE Link].
Haq SM, Dayal HH. Chronic liver disease and consumption of raw oysters: a potentially lethal combination--a review of Vibrio vulnificus septicemia. Am J Gastroenterol. 2005 May. 100(5):1195-9. [QxMD MEDLINE Link].
Partridge DG, Townsend R, Larkin S, Parsons HK. Vibrio vulnificus: an unusual mode of acquisition and novel use of rapid susceptibility testing. J Clin Pathol. 2009 Apr. 62(4):370-2. [QxMD MEDLINE Link].
Choi HJ, Lee DK, Lee MW, Choi JH, Moon KC, Koh JK. Vibrio vulnificus septicemia presenting as purpura fulminans. J Dermatol. 2005 Jan. 32(1):48-51. [QxMD MEDLINE Link].
Tajiri T, Tate G, Akita H, et al. Autopsy cases of fulminant-type bacterial infection with necrotizing fasciitis: group A (beta) hemolytic Streptococcus pyogenes versus Vibrio vulnificus infection. Pathol Int. 2008 Mar. 58(3):196-202. [QxMD MEDLINE Link].
Kitamura C, Yamauchi Y, Yamaguchi T, Aida Y, Ito K, Ishizawa Y, et al. Successful Treatment of a Case of Necrotizing Fasciitis due to Vibrio vulnificus in a Cold Climate in Japan. Intern Med. 2016. 55 (8):1007-10. [QxMD MEDLINE Link].
Tsai YH, Wen-Wei Hsu R, Huang KC, Huang TJ. Comparison of necrotizing fasciitis and sepsis caused by Vibrio vulnificus and Staphylococcus aureus. J Bone Joint Surg Am. 2011 Feb. 93(3):274-84. [QxMD MEDLINE Link].
de Klerk A. Should a patient have access to his medical records. Med Law. 1989. 8 (5):475-83. [QxMD MEDLINE Link].
Inoue H. Vibrio vulnificus infection of the hand. J Orthop Sci. 2006 Jan. 11(1):85-7. [QxMD MEDLINE Link].
Tsai YH, Hsu RW, Huang TJ, et al. Necrotizing soft-tissue infections and sepsis caused by Vibrio vulnificus compared with those caused by Aeromonas species. J Bone Joint Surg Am. 2007 Mar. 89(3):631-6. [QxMD MEDLINE Link].
Tsai YH, Chen PH, Yu PA, Chen CL, Kuo LT, Huang KC. A multiplex PCR assay for detection of Vibrio vulnificus, Aeromonas hydrophila, methicillin-resistant Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus agalactiae from the isolates of patients with necrotizing fasciitis. Int J Infect Dis. 2019 Apr. 81:73-80. [QxMD MEDLINE Link].
Lee YC, Hor LI, Chiu HY, Lee JW, Shieh SJ. Prognostic factor of mortality and its clinical implications in patients with necrotizing fasciitis caused by Vibrio vulnificus. Eur J Clin Microbiol Infect Dis. 2014 Jun. 33(6):1011-8. [QxMD MEDLINE Link].
Hong G, Wu B, Lu C, Li M, Zhao G, Lu Z. Emergency treatment of 16 patients with necrotizing fasciitis caused by Vibrio vulnificus infection complicated with septic shock. Chin Med J (Engl). 2014 May. 127(10):1984-6. [QxMD MEDLINE Link].
[Guideline] American Medical Association; American Nurses Association-American Nurses Foundation; Centers for Disease Control and Prevention; et al. Diagnosis and management of foodborne illnesses: a primer for physicians and other health care professionals. MMWR Recomm Rep. 2004 Apr 16. 53:1-33. [QxMD MEDLINE Link].
[Guideline] Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014 Jul 15. 59(2):e10-52. [QxMD MEDLINE Link].
Prutkin JM, Haq R. A dish best served hot. Am J Med. 2006 Apr. 119(4):307-9. [QxMD MEDLINE Link].
Mouzin E, Mascola L, Tormey MP, Dassey DE. Prevention of Vibrio vulnificus infections. Assessment of regulatory educational strategies. JAMA. 1997 Aug 20. 278(7):576-8. [QxMD MEDLINE Link].
Cai R, Liu N, Guo P, Liao K, Li M, Zhu J, et al. Protective Effects of Chicken Egg Yolk Immunoglobulins (IgYs) against Vibrio vulnificus Infections. J Immunol Res. 2021. 2021:6678513. [QxMD MEDLINE Link].
Lee TH, Kim MH, Lee CS, Lee JH, Rhee JH, Chung KM. Protection against Vibrio vulnificus infection by active and passive immunization with the C-terminal region of the RtxA1/MARTXVv protein. Vaccine. 2014 Jan 3. 32(2):271-6. [QxMD MEDLINE Link].
Kim HJ, Kim YT, Kim HB, Choi SH, Lee JH. Characterization of bacteriophage VVP001 and its application for the inhibition of Vibrio vulnificus causing seafood-borne diseases. Food Microbiol. 2021 Apr. 94:103630. [QxMD MEDLINE Link].
Tang HJ, Chen CC, Lai CC, Zhang CC, Weng TC, Chiu YH, et al. In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus. J Microbiol Immunol Infect. 2018 Feb. 51 (1):76-81. [QxMD MEDLINE Link].

Media Gallery

Vibrio infections. Early bullous lesions appear over the dorsum of the foot of a patient with cirrhosis.

of 1

Author

Robert A Schwartz, MD, MPH Professor and Head of Dermatology, Professor of Pathology, Professor of Pediatrics, Professor of Medicine, Rutgers New Jersey Medical School

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, New York Academy of Medicine, Royal College of Physicians of Edinburgh, Sigma Xi, The Scientific Research Honor Society

Disclosure: Nothing to disclose.

Coauthor(s)

Cris Jagar, MD Staff Physician, Department of Psychiatry, Trinitas Regional Medical Center

Disclosure: Nothing to disclose.

Specialty Editor Board

David F Butler, MD Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, Association of Military Dermatologists, Phi Beta Kappa, Texas Dermatological Society

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, American College of Rheumatology

Disclosure: Received income in an amount equal to or greater than $250 from: Biogen US (Adjudicator for study entry cutaneous lupus erythematosus); Priovant (Adjudicator for entry into a dermatomyositis study); IQVIA (Serono - adjudicator for a study of cutaneous LE) <br/>Received honoraria from UpToDate for author/editor; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for these trust accounts for: Stocks held in various trust accounts: Allergen; Amgen; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble;; Celgene; Gilead; CVS; Walgreens; Bristol-Myers Squibb.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Craig A Elmets, MD Professor and Chair, Department of Dermatology, Director, Chemoprevention Program Director, Comprehensive Cancer Center, UAB Skin Diseases Research Center, University of Alabama at Birmingham School of Medicine

Craig A Elmets, MD is a member of the following medical societies: American Academy of Dermatology, American Association of Immunologists, American College of Physicians, American Federation for Medical Research, Society for Investigative Dermatology

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: University of Alabama at Birmingham; University of Alabama Health Services Foundation<br/>Serve(d) as a speaker or a member of a speakers bureau for: Ferndale Laboratories<br/>Received research grant from: NIH, Veterans Administration, California Grape Assn<br/>Received consulting fee from Astellas for review panel membership; Received salary from Massachusetts Medical Society for employment; Received salary from UpToDate for employment. for: Astellas.